Apolipoprotein B

Also written ApoB

CardiovascularMeasured in mg/dL

What it measures

Every atherogenic lipoprotein particle carries exactly one apoB molecule, so an apoB measurement is a direct count of the particles capable of depositing cholesterol in an artery wall.

Why it matters

Two people with identical LDL cholesterol can carry very different particle counts. When the two measures disagree, apoB is the better predictor of cardiovascular events, which is why it has moved from specialist use into routine consumer panels.

Where the claimed ranges actually sit

Measured in mg/dL. Each row is one claim about where your result should fall.

What a laboratory reportsWhat a seller markets as “optimal”

Laboratory reference range< 90 mg/dL

Laboratory reference intervals; cutoffs vary by lab and by assumed risk category

Under 80 mg/dLA< 80 mg/dL

Longevity testing platforms and preventive cardiology clinics

Under 60 mg/dLB< 60 mg/dL

Aggressive optimization clinics and supplement protocols

›View as table

Claim	Range	Source
Laboratory reference range	< 90 mg/dL	Laboratory reference intervals; cutoffs vary by lab and by assumed risk category
Under 80 mg/dL	< 80 mg/dL	Longevity testing platforms and preventive cardiology clinics
Under 60 mg/dL	< 60 mg/dL	Aggressive optimization clinics and supplement protocols

Where the sources disagree

There is unusually little scientific disagreement here: apoB is one of the best-validated markers in the registry. The disagreement is about who should act on it and at what threshold. A laboratory reports a population-derived cutoff around 90 mg/dL. A preventive clinic markets 80, then 60. None of those numbers mean anything without your absolute risk, your age, and your family history, and a number sold as a universal target is a marketing decision rather than a clinical one.

The marketed ranges, examined

Each claim gets its strongest possible case before it gets its criticism. Several of these are substantially correct.

Under 80 mg/dL

Promoted by longevity testing platforms and preventive cardiology clinics

ATrial-supported

The strongest case for it

ApoB counts the number of atherogenic particles directly, and both randomized trials and Mendelian randomization support a causal, dose-dependent relationship with atherosclerotic events. Lower really is better across the observed range.

What it leaves out

The specific number depends entirely on your absolute risk. An 80 mg/dL target is reasonable for someone at elevated risk and largely irrelevant for a healthy 28-year-old, but it is often marketed as a universal target.

Under 60 mg/dL

Promoted by aggressive optimization clinics and supplement protocols

BAssociation only

The strongest case for it

Secondary-prevention trials have driven apoB this low without a floor effect appearing, and very low lifetime particle exposure tracks with very low event rates.

What it leaves out

This is a target derived from high-risk populations already on therapy. Applying it to primary prevention in healthy people means recommending medication for a risk reduction that has not been measured in that group.

Before you act on your result

ApoB is meaningfully more useful than LDL-C in people with high triglycerides, diabetes, or metabolic syndrome, where the two measures diverge most.
Non-fasting measurement is acceptable, unlike calculated LDL-C.
A single elevated result is not a diagnosis. Biological variation between draws is real.

Last reviewed July 28, 2026How we grade evidence and attribute claims →

More in Cardiovascular

Lipoprotein(a)

Lp(a)

LDL Cholesterol

LDL-C

HDL Cholesterol

HDL-C

Triglycerides

The Mirror Brief

One email when a reference range changes, a panel claim is corrected, or a regulatory status actually moves, not when something is merely proposed. No sponsors from any company we rate.

Unsubscribe anytime. We never sell or share your address.